Additionally, Eli Lilly’s tirzepatide (Mounjaro® Eli Lilly and Company, Indianapolis, IN, USA), a dual GIP/GLP-1 receptor agonist, received approval in China for type II diabetes in 2024, following its U.S. approval in 2022. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.